Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

NCT05170256 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma
HER-2 Protein Overexpression
HER-2 Gene Amplification

Interventions

DRUG: Trastuzumab

Sponsor

Morten Mau-Sørensen

Collaborators

[object Object]
[object Object]
[object Object]